6th International

Lung Cancer Summit

4th October, Lausanne

REGISTRATION OPEN NOW

View Our ProgramRegister Now

Our Chairs Invite You To Join!

After the resounding success of the virtual International Lung Cancer Summit (ILCS), we extend a warm invitation to join us for the 6th edition of this engaging hybrid conference. Continuing our tradition of excellence, the ILCS will offer insights into the latest breakthroughs and developments in lung cancer treatment. This conference will harness digital platforms to foster meaningful engagement and networking opportunities for attendees from medical offices, universities, and institutes, allowing them to connect with esteemed medical oncologists and industry professionals at the forefront of lung cancer treatment and research. With distinguished speakers from the USA, Spain, UK, Italy, Netherlands, France, Austria, and Switzerland, the ILCS promises to be an invaluable platform for sharing knowledge and advancing seamless treatment practices.

Solange Peters, MD-PhD

Solange Peters, MD-PhD, is Professor and chair of Medical Oncology as well as the Thoracic Malignancies programme in the department of oncology at Lausanne University Hospital, Switzerland. She has authored numerous peer-reviewed manuscripts and book chapters, and serves as deputy editor of the Journal of Thoracic Oncology, and on the editorial board of several other oncology journals. Professor Peters is active in the educational programs of the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC), notably working as the current editor of the ESMO lung cancer clinical practice guidelines. She is the Chair of ESMO Women for Oncology Committee, and she is the youngest ESMO President ever, for a mandate in 2020-2021. She was also a member of the IASLC board of directors, and acts as vice president of the Swiss Group for Clinical Cancer Research lung group. She received both her doctorate in medicine and PhD from Lausanne University Hospital, Switzerland. After completing her clinical education in medical oncology and molecular biology in Switzerland and Italy, Professor Peters has specialized in thoracic tumors, lung cancer, and pleural tumors.

Alfredo Addeo, MD

Alfredo Addeo is the Head of the Oncology service in the Department of Oncology at the University Hospital of Geneva (HUG), Geneva Switzerland. He is the author of numerous national and international peer-reviewed publications in renowned scientific journals, including first- and last-author publications in the Journal of Clinical Oncology, Annals of Oncology and Lancet Oncology. He has acted as a reviewer for several international scientific journals, including Journal of Thoracic Oncology and JAMA Oncology, and is an associate editor for Frontiers in Thoracic Oncology and guest editor for Precision Cancer Medicine. Dr. Addeo is an active ESMO member and a member of the EORTC lung group. He actively participates in ETOP (European Thoracic Oncology Platform) and SAKK (the Swiss Group for Clinical Cancer Research) and is a researcher and co-investigator of several national and international studies.

Tentative PROGRAM

4th October 2024

All times are in Central European Time

10.00

Welcome by Chairs

Solange Peters & Alfredo Addeo

10.00

Advancements in Lung Cancer Diagnostics: Current Guidelines and Emerging Tests

tbd

10.30

Novel Therapeutic Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

Anne-Marie Dingemans (Netherlands)

10.50

Rare But Actionable: How To Target for RET, METex14 and NTRK

Roberto Ferrara (Italy)

11.20

Open Discussion & Coffee Break

11.30

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

Biagio Ricciuti (USA)

12.00

The Emerging Role of ADCs in Lung Cancer: Navigating Timing and Applications for Optimal Use

Jarushka Naidoo (Ireland)

13.30

Surgical Dilemmas in NSCLC: Defining Resectability for Optimal Patient Outcomes in the IO Era

Nuria maria novoa (spain)

14.00

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

Delvys Rodriguez Abreu (Spain)

15.00

Open Discussion & Coffee Break

15.20

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

  • We Must Seize Every Opportunity To Cease IO

    Giannis Mountzios (Greece)
  • We Must Maximize IO Benefits Through Prolonged Therapy

    Sandip Patel (USA)

15.50

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

Stephen Liu (USA)

16.15

Open Questions, Patient Cases & Guidelines

Panel Discussion With All

SAVE THE DATE

5 SGMO CME Credits

An application has been made to the UEMS EACCME® for CME accreditation of this event

This meeting is accredited and CME-certified! Add this event to your calendar by selecting your calendar and download your certificate of attendance after the conference.

Swiss Society of Medical Oncology: 5 credit points

Impressions of the ILCS 2023

Our VENUE

Join us live online or on site at the

Centre hospitalier universitaire vaudois – CHUV

Fondation ISREC, Bâtiment AGORA

Rue du Bugnon 25A

1005 Lausanne, Switzerland

Send us your questions for discussion

SEE YOU SOON: 4th October 2024

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

Follow Us For The Latest News on X & LinkedIn

FAQ

Will I be able to re-access the videos?

Absolutely, the content is recorded and swiftly made accessible on our virtual platform within 24 hours. This enables you to enjoy it on demand, allowing for repeated viewing at your convenience.

Does it cost me anything?

Access to our virtual platform is free of charge for healthcare professionals, students, scientists, and personnel from universities, hospitals, research labs, as well as policy and non-profit organizations, along with sponsoring partners. However, registrations from non-sponsoring industry representatives may be subject to a nominal fee.

Why do you need my details for registration?

To comply with Swiss and European regulations, we kindly ask for your information for verification purposes. This ensures that our initiatives are tailored to healthcare professionals and individuals engaged in the science, management, and treatment of cancer. Rest assured, we uphold strict confidentiality and will not disclose your personal details to any sponsor or third party. Your privacy is our priority – promised!

How can I get involved in the discussion?

If you are joining us onsite, you can raise your hand to ask a question during discussions, or if you’re tuning in virtually, simply submit your comments through the question box.